Evidence map›Paper›PMID 40660986›Full record

Trial reportZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2025

[A phase Ⅲ clinical study to evaluate the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of adults with chronic hepatitis C].

L Wei, J Shang, X An, G Q Zhang, Y J Guan, H X Piao, J L Jin, L Bai, X X Yang, D K Yang and 19 more

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

L WeiHepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China.
J ShangDepartment of Infection, Henan Provincial People's Hospital, Zhengzhou 450000, China.
X AnDepartment of Hepatology, Chongqing University Three Gorges Hospital, Chongqing 404000, China.
G Q ZhangDepartment of Infection, Luoyang Central Hospital, Luoyang 471000, China.
Y J GuanDepartment of Hepatology, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou 510060, China.
H X PiaoDepartment of Gastroenterology, Yanbian University Hospital, Yanji 133000, China.
J L JinDepartment of Hepatic-biliary-pancreatic Medicine, the First Hospital of Jilin University, Changchun 130000, China.
L BaiCentre of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, China.
X X YangDepartment of Infection, Sichuan Provincial People's Hospital, Chengdu 610072, China.
D K YangDepartment of Infection, the First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China.
X H LuoDepartment of Infection, Guizhou Provincial People's Hospital, Guiyang 550002, China.
S F YuanDepartment of Infection, Liuzhou People's Hospital, Liuzhou 545026, China.
Y R ZhaoHepatobiliary Center, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Y J MaDepartment of Gastroenterology, Zhengzhou People's Hospital, Zhengzhou 710068, China.
G M LiDepartment of Hepatology, Henan Provincial Infectious Disease Hospital, Zhengzhou 475001, China.
F LinDepartment of Infection, Hainan Provincial People's Hospital, Haikou 570311, China.
X P WuDepartment of Infection, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
J W GengDepartment of Infectious Diseases & Hepatology, Yunnan Provincial First People's Hospital, Kunming 650034, China.
G Z ZouDepartment of Hepatology, the Second Affiliated Hospital of Anhui Medical University, Hefei 230000, China.
J B ChangDepartment of Hepatology, Nanjing Second Hospital, Nanjing 211135, China.
Z J GongDepartment of Infection, Renmin Hospital of Wuhan University, Wuhan 430060, China.
X R MaoDepartment of Infection, the First Hospital of Lanzhou University, Lanzhou 730099, China.
J ZhuState Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co. ,Ltd, Dongguan 523871, China.
W T GuoState Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co. ,Ltd, Dongguan 523871, China.
Q W HeState Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co. ,Ltd, Dongguan 523871, China.
L LuoState Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co. ,Ltd, Dongguan 523871, China.
Y L ZhuangState Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co. ,Ltd, Dongguan 523871, China.
H M XieState Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co. ,Ltd, Dongguan 523871, China.
Y J ZhangState Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co. ,Ltd, Dongguan 523871, China.

Funding

Enterprise Key Laboratory of Anti-viral Drug Development for Guangdong Province 2020B1212070003
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiviral AgentsDrugs, Chinese HerbalHepatitis C, ChronicImidazolesAdultDouble-Blind MethodDrug Therapy, CombinationFemaleGenotypeHepacivirusHumansMaleMiddle AgedSustained Virologic ResponseTreatment OutcomeValineAntiviral AgentsDrugs, Chinese HerbalImidazolesValine

Identifiers

PMID40660986
PMCPMC12861850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.